Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BeOne Medicines Ltd. Director's Dealing 2024

Jun 26, 2024

30073_dirs_2024-06-26_2db1827d-f6b8-4391-b182-ccc11b8148a6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2024-06-24

Reporting Person: Wang Julia Aijun (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-06-24 American Depositary Shares S 899 $155.66 Disposed 0 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 432731 Direct

Footnotes

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.